Last reviewed · How we verify

4L PEG

Changhai Hospital · FDA-approved active Small molecule Quality 14/100

4L PEG, marketed by Changhai Hospital, is an osmotic laxative used for bowel evacuation. Its key strength lies in its mechanism of action, which effectively draws water into the colon to facilitate cleansing. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name4L PEG
Also known aspolyethylene glycol
SponsorChanghai Hospital
Drug classOsmotic laxative
TargetColon
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: